https://amphista.com/wp-content/uploads/2021/03/UPS.jpg
800
1000
ginealach
https://amphista.com/wp-content/uploads/2022/03/Amphista_Logo-300x270-1.png
ginealach2020-10-15 14:36:122021-03-16 17:03:31The rise and rise of TPD? Personal highlights from the 3rd Annual TPD Summit 14-15th October 2020Latest News
Upcoming Events
Amphista will be attending and/or presenting at the following conferences. If you would like to meet with us, please email info@amphista.com
Blog
https://amphista.com/wp-content/uploads/2021/03/UPS.jpg
800
1000
ginealach
https://amphista.com/wp-content/uploads/2022/03/Amphista_Logo-300x270-1.png
ginealach2020-10-15 14:36:122021-03-16 17:03:31The rise and rise of TPD? Personal highlights from the 3rd Annual TPD Summit 14-15th October 2020
https://amphista.com/wp-content/uploads/2021/03/Microtiter.jpg
800
1000
ginealach
https://amphista.com/wp-content/uploads/2022/03/Amphista_Logo-300x270-1.png
ginealach2020-10-11 14:32:292021-03-16 17:03:45It’s not rocket science
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein degraders into the clinic and building a robust pipeline Appointment follows achievement of three key milestones for Amphista in 2024 which demonstrated: in vivo efficacy, ability to target and degrade proteins in the CNS and novel mechanism of […]
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium
First presentation of a novel mechanism of action for the degradation of BRD9 – completely differentiated from cereblon- or VHL-based PROTACs Amphista’s bifunctional BRD9 degraders selectively induce BRD9 to DCAF16 proximity and serve as molecular glues, leading to strong and rapid degradation of BRD9 Discovery further underscores Amphista’s proprietary chemistry and high-quality science which is […]
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader Deep degradation of target protein is achieved in a rapid, sustained, and highly selective manner Successful achievement of efficient CNS delivery for multiple degraders and demonstration of significant degradation of target protein in the brain Cambridge, […]